Balaji Tamarappoo

Dr. Balaji Tamarappoo

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2014 in Journal of Nuclear Cardiology
Verified
Journal Article
Open access
PDF file
HSHelen Su
Helen Su
NGNatalia Gorodny
Natalia Gorodny
LGLuis Felipe Gomez
Luis Felipe Gomez
UGUmesh B. Gangadharmath
Umesh B. Gangadharmath
FMFanrong Mu
Fanrong Mu
BTBalaji Tamarappoo
Balaji Tamarappoo
Rupture of unstable atherosclerotic plaque that leads to stroke and myocardial infarction may be induced by macrophage infiltration and neovessel formation. A tracer that selectively binds to integrin αvβ3 a protein expressed by macrophages and neovascular endothelium may identify rupture prone plaque.

Verified
Journal Article
Open access
PDF file
ISIsabel Grace Scalia
Isabel Grace Scalia
BGBashaer Gheyath
Bashaer Gheyath
BTBalaji Tamarappoo
Balaji Tamarappoo
Rohit MoudgilRohit Moudgil
Rohit Moudgil
JOJames Otton
James Otton
CAChadi Ayoub
Chadi Ayoub
The long-term survivorship of patients diagnosed with cancer has improved due to accelerated detection and rapidly evolving cancer treatment strategies. As such, the evaluation and management of cancer therapy related complications has become increasingly important, including cardiovascular complications. These have been captured under the umbrella term “cardiotoxicity” and include left ventricular dysfunction and heart failure, acute coronary syndromes, valvular abnormalities, pericardial disease, arrhythmia, myocarditis, and vascular complications. These complications add to the burden of cardiovascular disease (CVD) or are risk factors patients with cancer treatment are presenting with. Of note, both pre- and newly developing CVD is of prognostic significance, not only from a cardiovascular perspective but also overall, potentially impacting the level of cancer therapy that is possible. Currently, there are varying recommendations and practices regarding CVD risk assessment and mitigating strategies throughout the cancer continuum. This article provides an overview on this topic, in particular, the role of cardiac imaging in the care of the patient with cancer. Furthermore, it summarizes the current evidence on the spectrum, prevention, and management of chemotherapy-related adverse cardiac effects.